Cytokinetics, Inc. (CYTK)
72.72
-1.23
(-1.66%)
USD |
NASDAQ |
Sep 04, 16:00
72.70
-0.02
(-0.03%)
After-Hours: 20:00
Cytokinetics SG&A Expense (TTM) : 370.47M for June 30, 2026
SG&A Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 370.47M |
| March 31, 2026 | 331.80M |
| December 31, 2025 | 284.27M |
| September 30, 2025 | 254.89M |
| June 30, 2025 | 242.08M |
| March 31, 2025 | 227.18M |
| December 31, 2024 | 215.31M |
| September 30, 2024 | 197.09M |
| June 30, 2024 | 180.55M |
| March 31, 2024 | 169.45M |
| December 31, 2023 | 173.61M |
| September 30, 2023 | 183.47M |
| June 30, 2023 | 191.58M |
| March 31, 2023 | 194.57M |
| December 31, 2022 | 177.98M |
| September 30, 2022 | 157.81M |
| June 30, 2022 | 135.79M |
| March 31, 2022 | 114.28M |
| December 31, 2021 | 96.80M |
| September 30, 2021 | 76.90M |
| June 30, 2021 | 63.00M |
| March 31, 2021 | 55.97M |
| December 31, 2020 | 52.82M |
| September 30, 2020 | 49.50M |
| June 30, 2020 | 46.95M |
| Date | Value |
|---|---|
| March 31, 2020 | 42.62M |
| December 31, 2019 | 39.61M |
| September 30, 2019 | 36.58M |
| June 30, 2019 | 34.00M |
| March 31, 2019 | 32.20M |
| December 31, 2018 | 32.03M |
| September 30, 2018 | 34.73M |
| June 30, 2018 | 37.23M |
| March 31, 2018 | 37.62M |
| December 31, 2017 | 36.47M |
| September 30, 2017 | 32.88M |
| June 30, 2017 | 30.44M |
| March 31, 2017 | 29.10M |
| December 31, 2016 | 27.82M |
| September 30, 2016 | 26.68M |
| June 30, 2016 | 24.74M |
| March 31, 2016 | 22.14M |
| December 31, 2015 | 19.67M |
| September 30, 2015 | 18.70M |
| June 30, 2015 | 17.41M |
| March 31, 2015 | 17.38M |
| December 31, 2014 | 17.27M |
| September 30, 2014 | 16.80M |
| June 30, 2014 | 16.44M |
| March 31, 2014 | 15.72M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Bristol Myers Squibb Co. | 7.413B |
| Krystal Biotech, Inc. | 159.89M |
| Ionis Pharmaceuticals, Inc. | 527.56M |
| Vertex Pharmaceuticals, Inc. | 2.008B |
| Alnylam Pharmaceuticals, Inc. | 1.318B |